Ignite Creation Date:
2024-05-06 @ 7:59 PM
Last Modification Date:
2024-10-26 @ 3:18 PM
Study NCT ID:
NCT06214156
Status:
RECRUITING
Last Update Posted:
2024-03-22
First Post:
2024-01-09
Brief Title:
A Clinical Study of T3011 in Subjects With Advanced Melanoma
Sponsor:
Shanghai Pharmaceuticals Holding Co Ltd
Organization:
Shanghai Pharmaceuticals Holding Co Ltd
Study Overview
Official Title:
A Phase IbIIa Clinical Study to Evaluate the Tolerability Safety and Preliminary Efficacy of T3011 in Subjects With Advanced Melanoma
Status:
RECRUITING
Status Verified Date:
2024-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This clinical study evaluated the tolerability safety and preliminary efficacy of T3011 in subjects with advanced melanoma
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None